KR102359855B1 - 감염 치료용 치료제 - Google Patents

감염 치료용 치료제 Download PDF

Info

Publication number
KR102359855B1
KR102359855B1 KR1020167030614A KR20167030614A KR102359855B1 KR 102359855 B1 KR102359855 B1 KR 102359855B1 KR 1020167030614 A KR1020167030614 A KR 1020167030614A KR 20167030614 A KR20167030614 A KR 20167030614A KR 102359855 B1 KR102359855 B1 KR 102359855B1
Authority
KR
South Korea
Prior art keywords
peroxide
carrier
acetyl
donor
micro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167030614A
Other languages
English (en)
Korean (ko)
Other versions
KR20160144408A (ko
Inventor
아드리안 네빌 펠로우스
Original Assignee
아가 나노테크 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아가 나노테크 리미티드 filed Critical 아가 나노테크 리미티드
Priority to KR1020227003691A priority Critical patent/KR102482597B1/ko
Publication of KR20160144408A publication Critical patent/KR20160144408A/ko
Application granted granted Critical
Publication of KR102359855B1 publication Critical patent/KR102359855B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/132Amines having two or more amino groups, e.g. spermidine, putrescine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/327Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/40Peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020167030614A 2014-04-01 2015-03-24 감염 치료용 치료제 Active KR102359855B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227003691A KR102482597B1 (ko) 2014-04-01 2015-03-24 감염 치료용 치료제

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1405874.7 2014-04-01
GBGB1405874.7A GB201405874D0 (en) 2014-04-01 2014-04-01 A therapeutic agent for use in the treatment of infections
GB1415063.5 2014-08-26
GBGB1415063.5A GB201415063D0 (en) 2014-04-01 2014-08-26 A therapeutic agent for use in the treatment of infections
PCT/GB2015/000100 WO2015150722A1 (en) 2014-04-01 2015-03-24 A therapeutic agent for use in the treatment of infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227003691A Division KR102482597B1 (ko) 2014-04-01 2015-03-24 감염 치료용 치료제

Publications (2)

Publication Number Publication Date
KR20160144408A KR20160144408A (ko) 2016-12-16
KR102359855B1 true KR102359855B1 (ko) 2022-02-08

Family

ID=50737835

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167030614A Active KR102359855B1 (ko) 2014-04-01 2015-03-24 감염 치료용 치료제
KR1020227003691A Active KR102482597B1 (ko) 2014-04-01 2015-03-24 감염 치료용 치료제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227003691A Active KR102482597B1 (ko) 2014-04-01 2015-03-24 감염 치료용 치료제

Country Status (16)

Country Link
US (2) US9913805B2 (https=)
EP (2) EP3848022B1 (https=)
JP (1) JP6573286B2 (https=)
KR (2) KR102359855B1 (https=)
CN (1) CN106456557B (https=)
AU (1) AU2015242495B2 (https=)
CA (1) CA2943431C (https=)
DK (1) DK3125874T3 (https=)
ES (2) ES2855985T3 (https=)
GB (3) GB201405874D0 (https=)
IL (1) IL247969B (https=)
MX (1) MX2016012757A (https=)
NZ (1) NZ724298A (https=)
SG (2) SG11201608093WA (https=)
WO (1) WO2015150722A1 (https=)
ZA (1) ZA201606387B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12551501B2 (en) 2012-02-17 2026-02-17 Wiab Water Innovation Ab Compositions and methods for treating biofilms without inducing antimicrobial resistance
GB201405874D0 (en) * 2014-04-01 2014-05-14 Aga Nanotech Ltd A therapeutic agent for use in the treatment of infections
CN107281220B (zh) * 2016-03-31 2020-02-14 中国科学院上海硅酸盐研究所 一种介孔氧化硅基活性氧(ros)放疗增敏剂及其制备方法
CN106860032B (zh) * 2016-10-25 2021-04-09 咏达生医材料股份有限公司 一种气态皮肤供氧美白产品及其应用
US12605403B2 (en) 2016-12-22 2026-04-21 Wiab Water Innovation Ab Compositions and methods for treating transient biofilms
JP2019194162A (ja) * 2018-05-01 2019-11-07 ツァ ギャリー 肌の酸素供給による美白及び加熱機能を備えた通気性材料
JP7372706B2 (ja) 2019-10-10 2023-11-01 アルファ タウ メディカル リミテッド 放射線治療源の湿式調製
GB2592911B (en) * 2020-02-28 2023-06-28 Aga Nanotech Ltd A plasma-activatable wound dressing for treatment of infections
GB202005556D0 (en) 2020-04-16 2020-06-03 Aga Nanotech Ltd Covid face mask

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088498A1 (en) * 2004-10-27 2006-04-27 Truox, Inc. Anti-microbial composition using in-situ generation of an oxidizing agent

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007777A1 (en) * 1995-08-15 1997-03-06 Robert Eric Montgomery Peroxidase-activating oral compositions
DE59912558D1 (de) * 1999-07-02 2005-10-20 Cognis Ip Man Gmbh Mikrokapseln - IV
EP1187602A4 (en) * 2000-04-18 2004-09-15 Peptron Inc SUSTAINABLE RELEASE INJECTABLE PHARMACEUTICAL COMPOSITION AND METHODS OF PREPARING THE SAME
KR100342746B1 (ko) * 2000-06-27 2002-07-03 김찬화 인슐린의 방출제어제제 및 그 방법
GB0411304D0 (en) * 2004-05-21 2004-06-23 Fellows Adrian N An antimicrobial composition
EP1919507A2 (en) * 2005-08-04 2008-05-14 Thomas William Rademacher Nanoparticles comprising antibacterial ligands
KR20070071225A (ko) * 2005-12-29 2007-07-04 애경산업(주) 치아 미백용 조성물
GB0711952D0 (en) * 2007-06-20 2007-08-01 King S College London Microspheres
EP2244698A1 (en) * 2008-02-25 2010-11-03 The University Of North Carolina At Charlotte Office Of Technology Transfer Biodegradable therapeutic nanoparticles containing an antimicrobial agent
JP2011528275A (ja) * 2008-07-17 2011-11-17 ミセル テクノロジーズ,インク. 薬物送達医療デバイス
US8969282B2 (en) * 2009-02-05 2015-03-03 American Sterilizer Company Low odor, hard surface sporicide
US8889161B2 (en) * 2009-04-27 2014-11-18 Premier Dental Products Company Microencapsulated compositions and methods for tissue mineralization
KR101136028B1 (ko) * 2009-04-27 2012-04-18 한양대학교 산학협력단 다공성 마이크로스피어의 제조방법
NZ600269A (en) 2009-05-20 2014-02-28 Dec Int Nz Ltd Delivery device for treatment of mastitis
WO2011100327A2 (en) * 2010-02-09 2011-08-18 The Regents Of The University Of Michigan Nano-fibrous microspheres and methods for making the same
WO2012005594A2 (en) * 2010-07-09 2012-01-12 Innocore Technologies B.V. Biodegradable phase separated segmented multi block co-polymers and release of biologically active polypeptides
WO2012074588A2 (en) * 2010-08-30 2012-06-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
GB201405874D0 (en) * 2014-04-01 2014-05-14 Aga Nanotech Ltd A therapeutic agent for use in the treatment of infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088498A1 (en) * 2004-10-27 2006-04-27 Truox, Inc. Anti-microbial composition using in-situ generation of an oxidizing agent

Also Published As

Publication number Publication date
NZ724298A (en) 2022-07-01
JP6573286B2 (ja) 2019-09-11
ES2953755T3 (es) 2023-11-15
WO2015150722A1 (en) 2015-10-08
JP2017510648A (ja) 2017-04-13
EP3848022A1 (en) 2021-07-14
ES2855985T3 (es) 2021-09-27
EP3125874A1 (en) 2017-02-08
AU2015242495A1 (en) 2016-10-06
CA2943431C (en) 2022-08-23
KR20160144408A (ko) 2016-12-16
KR20220021029A (ko) 2022-02-21
GB201415063D0 (en) 2014-10-08
DK3125874T3 (da) 2021-03-22
GB2538923B (en) 2020-03-25
US10933026B2 (en) 2021-03-02
IL247969B (en) 2018-12-31
CN106456557A (zh) 2017-02-22
US20170079930A1 (en) 2017-03-23
GB201405874D0 (en) 2014-05-14
SG11201608093WA (en) 2016-10-28
GB201617053D0 (en) 2016-11-23
MX2016012757A (es) 2017-04-27
ZA201606387B (en) 2017-11-29
GB2538923A (en) 2016-11-30
CN106456557B (zh) 2021-02-05
US20180207105A1 (en) 2018-07-26
EP3848022B1 (en) 2023-06-07
EP3125874B1 (en) 2020-12-30
EP3848022C0 (en) 2023-06-07
KR102482597B1 (ko) 2022-12-29
AU2015242495B2 (en) 2020-04-30
SG10201801524PA (en) 2018-04-27
CA2943431A1 (en) 2015-10-08
US9913805B2 (en) 2018-03-13

Similar Documents

Publication Publication Date Title
KR102359855B1 (ko) 감염 치료용 치료제
Yuan et al. Near-infrared light-triggered nitric-oxide-enhanced photodynamic therapy and low-temperature photothermal therapy for biofilm elimination
Li et al. Nano–bio interactions: biofilm‐targeted antibacterial nanomaterials
Mondal et al. Antimicrobial nanoparticles: current landscape and future challenges
Dai et al. Single continuous near-infrared laser-triggered photodynamic and photothermal ablation of antibiotic-resistant bacteria using effective targeted copper sulfide nanoclusters
Li et al. Biguanide-derived polymeric nanoparticles kill MRSA biofilm and suppress infection in vivo
Singh et al. Nanoparticle based drug delivery system: advantages and applications
Xue et al. An exceptional broad-spectrum nanobiocide for multimodal and synergistic inactivation of drug-resistant bacteria
Shende et al. Polymeric nanodroplets: an emerging trend in gaseous delivery system
Sofokleous et al. Sustained antimicrobial activity and reduced toxicity of oxidative biocides through biodegradable microparticles
Mahavir et al. Application of nanostructures in antimicrobial therapy
Safaran et al. Advances in polymeric and non-polymeric nanocarriers for the magnified delivery of levofloxacin against bacterial infection
Shu et al. Advanced coacervation-driven nanoscale polymeric assemblies for biomedical applications
Chan et al. Applications of nanoparticles for antimicrobial activity and drug delivery
HK40052395A (en) A therapeutic agent for use in the treatment of infections
HK1233167A1 (en) A therapeutic agent for use in the treatment of infections
HK1233167B (zh) 在感染的治疗中使用的治疗剂
CN119345112B (zh) 一种载有热休克蛋白抑制剂的脂质体水凝胶及其制备与应用
Mandal Gold nanomaterials as drug delivery system against diseases
ES2962702B2 (es) Nanoparticulas para la liberacion controlada de curcumina, procedimiento de preparacion y uso de las mismas
Huang et al. Reduction‐Triggered Breakable Micelles of Amphiphilic Polyamide Amine‐g‐Polyethylene Glycol for Methotrexate Delivery
Liu Adaptive antimicrobial nanocarriers for the control of infectious biofilms
Bhande et al. Nanomaterials: A Ray of Hope in Infectious Disease Treatment
Katiyar et al. Porous silica and related composites for topical drug delivery
Stewart Co-Assembled Drug-Silica Materials for Antimicrobial and Antidegradative Dental Applications

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161101

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200312

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210521

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20211102

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220203

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220203

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220204

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250114

Start annual number: 4

End annual number: 4